Insider Selling: Milestone Pharmaceuticals (NASDAQ:MIST) COO Sells $134,576.24 in Stock

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) COO Jeffrey Edward Nelson sold 58,007 shares of the stock in a transaction on Monday, December 15th. The stock was sold at an average price of $2.32, for a total transaction of $134,576.24. Following the completion of the transaction, the chief operating officer directly owned 41,993 shares in the company, valued at $97,423.76. The trade was a 58.01% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Jeffrey Edward Nelson also recently made the following trade(s):

• On Monday, January 26th, Jeffrey Edward Nelson sold 12,245 shares of Milestone Pharmaceuticals stock. The stock was sold at an average price of $1.93, for a total transaction of $23,632.85.

Milestone Pharmaceuticals Stock Up 1.1%

Shares of NASDAQ:MIST opened at $1.91 on Friday. The firm has a market capitalization of $162.67 million, a PE ratio of -2.33 and a beta of 0.44. The company has a debt-to-equity ratio of 2.74, a quick ratio of 8.24 and a current ratio of 8.24. Milestone Pharmaceuticals Inc. has a 52-week low of $0.63 and a 52-week high of $3.06. The firm has a fifty day moving average of $2.22 and a 200 day moving average of $1.97.

Milestone Pharmaceuticals (NASDAQ:MIST) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.05. As a group, research analysts anticipate that Milestone Pharmaceuticals Inc. will post -0.62 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in MIST. Sapient Capital LLC purchased a new stake in shares of Milestone Pharmaceuticals in the 3rd quarter worth about $25,000. Bank of America Corp DE increased its position in shares of Milestone Pharmaceuticals by 200,550.0% during the third quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock valued at $32,000 after buying an additional 16,044 shares during the period. Stephenson & Company Inc. bought a new position in Milestone Pharmaceuticals in the third quarter worth about $40,000. Creative Planning lifted its holdings in Milestone Pharmaceuticals by 74.6% in the second quarter. Creative Planning now owns 23,410 shares of the company’s stock worth $45,000 after buying an additional 10,000 shares during the period. Finally, Bay Rivers Group boosted its position in Milestone Pharmaceuticals by 72.9% during the 4th quarter. Bay Rivers Group now owns 28,861 shares of the company’s stock valued at $58,000 after acquiring an additional 12,170 shares in the last quarter. 86.18% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on MIST. TD Cowen upgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, December 15th. Zacks Research upgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, January 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research note on Monday, December 29th. Wells Fargo & Company boosted their target price on Milestone Pharmaceuticals from $4.00 to $8.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. Finally, HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of Milestone Pharmaceuticals in a report on Tuesday, January 6th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Milestone Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $8.00.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.